Atossa Therapeutics (ATOS) Expected to Announce Earnings on Monday

Atossa Therapeutics (NASDAQ:ATOS) is anticipated to release its earnings data before the market opens on Monday, April 7th. Analysts expect Atossa Therapeutics to post earnings of ($0.06) per share for the quarter.

Atossa Therapeutics (NASDAQ:ATOS) last issued its quarterly earnings results on Tuesday, March 25th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. On average, analysts expect Atossa Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Atossa Therapeutics Stock Down 0.3 %

ATOS stock opened at $0.70 on Monday. The stock’s 50 day moving average is $0.79 and its two-hundred day moving average is $1.10. Atossa Therapeutics has a 52-week low of $0.66 and a 52-week high of $2.31. The company has a market capitalization of $89.93 million, a PE ratio of -3.16 and a beta of 1.20.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Atossa Therapeutics stock. Bank of America Corp DE boosted its holdings in Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 51.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 111,475 shares of the company’s stock after purchasing an additional 37,809 shares during the quarter. Bank of America Corp DE owned approximately 0.09% of Atossa Therapeutics worth $105,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 12.74% of the company’s stock.

Wall Street Analyst Weigh In

ATOS has been the topic of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Atossa Therapeutics in a report on Wednesday, March 26th. Ascendiant Capital Markets boosted their target price on shares of Atossa Therapeutics from $6.50 to $7.00 and gave the stock a “buy” rating in a research report on Monday, December 9th.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.